

Karin Reif

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/234675/publications.pdf>

Version: 2024-02-01

37
papers

4,003
citations

186265

28
h-index

330143

37
g-index

37
all docs

37
docs citations

37
times ranked

4641
citing authors

#	ARTICLE	IF	CITATIONS
1	Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1588-1597.	2.8	12
2	Discovery of GDC-0853: A Potent, Selective, and Noncovalent Brutonâ€™s Tyrosine Kinase Inhibitor in Early Clinical Development. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2227-2245.	6.4	177
3	Discovery of Potent and Selective Tricyclic Inhibitors of Brutonâ€™s Tyrosine Kinase with Improved Druglike Properties. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 608-613.	2.8	26
4	Brutonâ€™s Tyrosine Kinase Small Molecule Inhibitors Induce a Distinct Pancreatic Toxicity in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 360, 226-238.	2.5	19
5	Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cellâ€™ associated damage in IFNÎ±-driven lupus nephritis. <i>JCI Insight</i> , 2017, 2, e90111.	5.0	65
6	Preclinical Safety Profile of a Depleting Antibody against CRTh2 for Asthma: Well Tolerated Despite Unexpected CRTh2 Expression on Vascular Pericytes in the Central Nervous System and Gastric Mucosa. <i>Toxicological Sciences</i> , 2016, 152, 72-84.	3.1	7
7	Automated Affinity Capture and On-Tip Digestion to Accurately Quantitate <i>in Vivo</i> Deamidation of Therapeutic Antibodies. <i>Analytical Chemistry</i> , 2016, 88, 11521-11526.	6.5	29
8	Discovery of highly potent and selective Brutonâ€™s tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 575-579.	2.2	34
9	Depletion of major pathogenic cells in asthma by targeting CRTh2. <i>JCI Insight</i> , 2016, 1, e86689.	5.0	26
10	Potent and selective Brutonâ€™s tyrosine kinase inhibitors: Discovery of GDC-0834. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 1333-1337.	2.2	55
11	Identification of GNE-293, a potent and selective PI3KÎ³ inhibitor: Navigating <i>in vitro</i> genotoxicity while improving potency and selectivity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 4953-4959.	2.2	27
12	Potent and selective inhibitors of PI3KÎ³: Obtaining isoform selectivity from the affinity pocket and tryptophan shelf. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 4296-4302.	2.2	48
13	Discovery of Novel PI3-Kinase Î³ Specific Inhibitors for the Treatment of Rheumatoid Arthritis: Taming CYP3A4 Time-Dependent Inhibition. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 5887-5900.	6.4	61
14	Specific Btk inhibition suppresses B cellâ€™ and myeloid cellâ€™ mediated arthritis. <i>Nature Chemical Biology</i> , 2011, 7, 41-50.	8.0	302
15	Antiarthritis Effect of a Novel Bruton's Tyrosine Kinase (BTK) Inhibitor in Rat Collagen-Induced Arthritis and Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling: Relationships between Inhibition of BTK Phosphorylation and Efficacy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 338, 154-163.	2.5	85
16	CD200R1 Agonist Attenuates Mechanisms of Chronic Disease in a Murine Model of Multiple Sclerosis. <i>Journal of Neuroscience</i> , 2010, 30, 2025-2038.	3.6	71
17	Cutting Edge: Differential Roles for Phosphoinositide 3-Kinases, p110Î³ and p110Î´, in Lymphocyte Chemotaxis and Homing. <i>Journal of Immunology</i> , 2004, 173, 2236-2240.	0.8	217
18	The CDM protein DOCK2 in lymphocyte migration. <i>Trends in Cell Biology</i> , 2002, 12, 368-373.	7.9	83

#	ARTICLE	IF	CITATIONS
19	Balanced responsiveness to chemoattractants from adjacent zones determines B-cell position. <i>Nature</i> , 2002, 416, 94-99.	27.8	506
20	Follicular stromal cells and lymphocyte homing to follicles. <i>Immunological Reviews</i> , 2000, 176, 181-193.	6.0	365
21	RGS Molecule Expression in Murine B Lymphocytes and Ability to Down-Regulate Chemotaxis to Lymphoid Chemokines. <i>Journal of Immunology</i> , 2000, 164, 4720-4729.	0.8	135
22	p21ras initiates Rac-1 but not phosphatidyl inositol 3 kinase/PKB, mediated signaling pathways in T lymphocytes. <i>Oncogene</i> , 1998, 17, 1731-1738.	5.9	38
23	Protection of CD95-mediated apoptosis by activation of phosphatidylinositide 3-kinase and protein kinase B. <i>European Journal of Immunology</i> , 1998, 28, 57-69.	2.9	103
24	Networking Rho Family GTPases in Lymphocytes. <i>Immunity</i> , 1998, 8, 395-401.	14.3	80
25	Phosphatidylinositol 3-Kinase Links the Interleukin-2 Receptor to Protein Kinase B and p70 S6 Kinase. <i>Journal of Biological Chemistry</i> , 1997, 272, 14426-14433.	3.4	161
26	45 Activation of the PI3K Effector Protein Kinase B Following Ligation of CD28 or Fas. <i>Biochemical Society Transactions</i> , 1997, 25, S589-S589.	3.4	9
27	Phosphatidylinositol 3-Kinase Couples the Interleukin-2 Receptor to the Cell Cycle Regulator E2F. <i>Immunity</i> , 1997, 7, 679-689.	14.3	383
28	A negative role for phosphoinositide 3-kinase in T-cell antigen receptor function. <i>Current Biology</i> , 1997, 7, 285-293.	3.9	56
29	Ligation of the T cell co-stimulatory receptor CD28 activates the serine-threonine protein kinase protein kinase B. <i>European Journal of Immunology</i> , 1997, 27, 2495-2501.	2.9	109
30	Phosphatidylinositol 3-kinase signals activate a selective subset of Rac/Rho-dependent effector pathways. <i>Current Biology</i> , 1996, 6, 1445-1455.	3.9	257
31	The protein interactions of the immunoglobulin receptor family tyrosine-based activation motifs present in the T cell receptor ζ subunits and the CD3 η , ϵ and μ chains. <i>European Journal of Immunology</i> , 1996, 26, 1063-1068.	2.9	98
32	The regulation and function of p21ras during T-cell activation and growth. <i>Trends in Immunology</i> , 1995, 16, 159-164.	7.5	155
33	Regulation of the Adapter Molecule Grb2 by the Fc γ R1 in the Mast Cell Line RBL2H3. <i>Journal of Biological Chemistry</i> , 1995, 270, 9500-9506.	3.4	46
34	SH3 domains of the adapter molecule Grb2 complex with two proteins in T cells: the guanine nucleotide exchange protein Sos and a 75-kDa protein that is a substrate for T cell antigen receptor-activated tyrosine kinases. <i>Journal of Biological Chemistry</i> , 1994, 269, 14081-7.	3.4	67
35	Regulation of PtdIns-3-kinase and the guanine nucleotide binding proteins p21ras during signal transduction by the T cell antigen receptor and the interleukin-2 receptor. <i>Seminars in Immunology</i> , 1993, 5, 319-326.	5.6	13
36	Divergent regulation of phosphatidylinositol 3-kinase P85 alpha and P85 beta isoforms upon T cell activation. <i>Journal of Biological Chemistry</i> , 1993, 268, 10780-8.	3.4	68

#	ARTICLE	IF	CITATIONS
37	In vitro mutagenesis of a xylanase from the extreme thermophile <i>Caldocellum saccharolyticum</i> . Applied Microbiology and Biotechnology, 1992, 36, 503-6.	3.6	10